191 related articles for article (PubMed ID: 34084223)
1. Integrin α5 promotes migration and invasion through the FAK/STAT3/AKT signaling pathway in icotinib-resistant non-small cell lung cancer cells.
Yang Y; Wang Y; Che X; Hou K; Wu J; Zheng C; Cheng Y; Liu Y; Hu X; Zhang J
Oncol Lett; 2021 Jul; 22(1):556. PubMed ID: 34084223
[TBL] [Abstract][Full Text] [Related]
2. Suppressed expression of Cbl-b by NF-κB mediates icotinib resistance in EGFR-mutant non-small-cell lung cancer.
Zhang T; Zheng C; Hou K; Wang J; Zhang Y; Fan Y; Zhao H; Qu X; Liu Y; Kang J; Che X; Hu X
Cell Biol Int; 2019 Feb; 43(2):98-107. PubMed ID: 29972257
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitor-induced IL-6/STAT3 activation decreases sensitivity of EGFR-mutant non-small cell lung cancer to icotinib.
Wang J; Wang Y; Zheng C; Hou K; Zhang T; Qu X; Liu Y; Kang J; Hu X; Che X
Cell Biol Int; 2018 Sep; 42(10):1292-1299. PubMed ID: 29885023
[TBL] [Abstract][Full Text] [Related]
4. Quinalizarin, a specific CK2 inhibitor, can reduce icotinib resistance in human lung adenocarcinoma cell lines.
Li K; Zhou F; Zhou Y; Zhang S; Li Q; Li Z; Liu L; Wu G; Meng R
Int J Mol Med; 2019 Aug; 44(2):437-446. PubMed ID: 31173177
[TBL] [Abstract][Full Text] [Related]
5. [The CK2 inhibitor quninalizarin enhances the anti-proliferative effect of icotinib on EGFR-TKIs-resistant cell lines and its underlying mechanisms].
Zhou Y; Zhang S; Li K; Li QW; Zhou FZ; Li ZY; Ma H; Dong XR; Liu L; Wu G; Meng R
Zhonghua Zhong Liu Za Zhi; 2016 Feb; 38(2):100-4. PubMed ID: 26899328
[TBL] [Abstract][Full Text] [Related]
6. Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling.
Sun X; Xu Y; Wang Y; Chen Q; Liu L; Bao Y
Med Sci Monit; 2018 May; 24():3193-3203. PubMed ID: 29763936
[TBL] [Abstract][Full Text] [Related]
7. Sequence-dependent synergistic cytotoxicity of icotinib and pemetrexed in human lung cancer cell lines in vitro and in vivo.
Liu T; Jin L; Lu W; Gan H; Lin Z; Chen M; Liu J; Zhang F; Wang S; Zhang H; Deng W; Chen H
J Exp Clin Cancer Res; 2019 Apr; 38(1):148. PubMed ID: 30953548
[TBL] [Abstract][Full Text] [Related]
8. Icotinib-resistant HCC827 cells produce exosomes with mRNA MET oncogenes and mediate the migration and invasion of NSCLC.
Yu Y; Abudula M; Li C; Chen Z; Zhang Y; Chen Y
Respir Res; 2019 Oct; 20(1):217. PubMed ID: 31606039
[TBL] [Abstract][Full Text] [Related]
9. Integrin β1-mediated acquired gefitinib resistance in non-small cell lung cancer cells occurs via the phosphoinositide 3-kinase-dependent pathway.
Deng QF; Su BO; Zhao YM; Tang L; Zhang J; Zhou CC
Oncol Lett; 2016 Jan; 11(1):535-542. PubMed ID: 26870244
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor β1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer.
Fu S; Liu C; Huang Q; Fan S; Tang H; Fu X; Ai B; Liao Y; Chu Q
Oncol Rep; 2018 Mar; 39(3):1313-1321. PubMed ID: 29328407
[TBL] [Abstract][Full Text] [Related]
11. Reduced expression levels of PTEN are associated with decreased sensitivity of HCC827 cells to icotinib.
Zhai Y; Zhang Y; Nan K; Liang X
Oncol Lett; 2017 May; 13(5):3233-3238. PubMed ID: 28521430
[TBL] [Abstract][Full Text] [Related]
12. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
[TBL] [Abstract][Full Text] [Related]
13. A positive feedback loop formed by NGFR and FOXP3 contributes to the resistance of non-small cell lung cancer to icotinib.
Huang J; Yu Q; Zhou Y; Chu Y; Jiang F; Zhu X; Zhang J; Wang Q
Transl Cancer Res; 2020 Feb; 9(2):1044-1052. PubMed ID: 35117449
[TBL] [Abstract][Full Text] [Related]
14. [Cetuximab in combination with icotinib overcomes the acquired resistance caused by EGFR T790M mutation in non-small cell lung cancer].
Wang M; Zhang L; Zhao X; Liu J; Chen Y; Wang C
Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):651-6. PubMed ID: 25564053
[TBL] [Abstract][Full Text] [Related]
15. Fut7 Promotes Adhesion and Invasion of Acute Lymphoblastic Leukemia Cells through the Integrin/Fak/Akt Pathway.
He F; Yi L; Lai C
Evid Based Complement Alternat Med; 2022; 2022():1864116. PubMed ID: 35795270
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-7 inhibits cell proliferation, migration and invasion in human non-small cell lung cancer cells by targeting FAK through ERK/MAPK signaling pathway.
Cao Q; Mao ZD; Shi YJ; Chen Y; Sun Y; Zhang Q; Song L; Peng LP
Oncotarget; 2016 Nov; 7(47):77468-77481. PubMed ID: 27764812
[TBL] [Abstract][Full Text] [Related]
17. Essential role for STAT3/FOXM1/ATG7 signaling-dependent autophagy in resistance to Icotinib.
Lyu X; Zeng L; Shi J; Ming Z; Li W; Liu B; Chen Y; Yuan B; Sun R; Yuan J; Zhao N; Yang X; Chen G; Yang S
J Exp Clin Cancer Res; 2022 Jun; 41(1):200. PubMed ID: 35690866
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
[TBL] [Abstract][Full Text] [Related]
19. Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities.
Hung WY; Chang JH; Cheng Y; Chen CK; Chen JQ; Hua KT; Cheng CW; Hsiao M; Chung CL; Lee WJ; Chien MH
Cell Physiol Biochem; 2018; 51(1):337-355. PubMed ID: 30453282
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts.
Tang N; Zhang Q; Fang S; Han X; Wang Z
Oncotarget; 2017 Feb; 8(6):9134-9143. PubMed ID: 27852073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
